Picture1.jpg
Curium Announces Exclusive Distribution Agreement in Switzerland with b.e. Imaging for PYLCLARI™, an Innovative 18F-PSMA Pet Tracer Indicated in Adults with Prostate Cancer
September 07, 2023 04:25 ET | Curium
PARIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into an exclusive rights agreement with b.e. Imaging, for the distribution...
Global Precision Oncology Market
Global Precision Oncology Research Report 2023: A Projected $225+ Billion Industry by 2031 - Explore Precision Oncology's Rise
September 04, 2023 05:28 ET | Research and Markets
Dublin, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The "Global Precision Oncology Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global precision...
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
September 01, 2023 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Global Oncology Devices Market
Global Oncology Devices Research Report 2022-2023 & 2029 - Enhanced Reimbursement Policies Fostering Demand Growth
August 28, 2023 05:43 ET | Research and Markets
Dublin, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The "Global Oncology Devices Market (2023 Edition): Analysis By Device Type (Ablation, Embolization, Others), Cancer Type (Breast, Uterine, Colon and...
HBC_Logo2020_RGB.png
Hofseth Biocare ASA: SUCCESSFULLY COMPLETED SEED ROUND CAPITAL RAISE IN HBC IMMUNOLOGY LLC AT $20M VALUATION FOR THE DEVELOPMENT OF A NEW PROSTATE CANCER CO-THERAPY
August 17, 2023 02:58 ET | Hofseth Biocare ASA
HBC Immunology LLC (“HBCI” or the “Company”), a majority owned subsidiary of Hofseth BioCare ASA (“HBC”), has successfully completed the required minimum seed capital financing of approx. USD 900,000...
Picture1.jpg
Curium Announces Achievement of Co-Primary Endpoints in Phase 2 of Its Phase 1/2 SOLAR Clinical Trial Imaging Men With Histologically-Proven Prostate Cancer Using Copper Cu 64 PSMA I&T
August 15, 2023 10:50 ET | Curium
PARIS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA...
myriad_S_stacked.png
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
August 15, 2023 07:05 ET | Myriad Genetics, Inc.
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,...
arvinas_logoART_lg.jpg
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023 07:00 ET | Arvinas Inc.
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2-...
arvinas_logoART_lg.jpg
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
July 31, 2023 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, July 31, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that the U.K. Innovative Licensing and Access Pathway...
Picture1.jpg
Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer
July 28, 2023 06:12 ET | Curium
PARIS, July 28, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that the European Commission has granted marketing authorization for PYLCLARI™ (INN: Piflufolastat...